Valsartan Patent Expiration
Valsartan is Used for managing hypertension and reducing cardiovascular mortality in stable patients with left ventricular failure or dysfunction post-myocardial infarction. It was first introduced by Novartis Pharmaceuticals Corp
Valsartan Patents
Given below is the list of patents protecting Valsartan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Diovan |
US6294197 (Pediatric) | Solid oral dosage forms of valsartan |
Dec 18, 2017
(Expired) | Novartis |
| Diovan | US6294197 | Solid oral dosage forms of valsartan |
Jun 18, 2017
(Expired) | Novartis |
| Diovan |
US5972990 (Pediatric) | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Apr 26, 2017
(Expired) | Novartis |
| Diovan | US5972990 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
Oct 26, 2016
(Expired) | Novartis |
| Diovan |
US5399578 (Pediatric) | Acyl compounds |
Sep 21, 2012
(Expired) | Novartis |
Valsartan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Valsartan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot | Jonathan Beaudoin | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet. | Center for Bioequivalence Studies and Clinical Research | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals | University of Alabama at Birmingham | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan | Virginia Commonwealth University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation | Brigham and Women's Hospital | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | University of Alabama at Birmingham | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2, PHASE3 |
| Repurposing Valsartan May Protect Against Pulmonary Hypertension | University of Washington | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| The ENCHANTMENT HIV Study | Massachusetts General Hospital | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |